| Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes RA DeFronzo, M Hompesch, S Kasichayanula, X Liu, Y Hong, M Pfister, ... Diabetes care 36 (10), 3169-3176, 2013 | 346 | 2013 |
| Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin D Devineni, L Morrow, M Hompesch, D Skee, A Vandebosch, J Murphy, ... Diabetes, Obesity and Metabolism 14 (6), 539-545, 2012 | 281 | 2012 |
| Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes MA Nauck, M Hompesch, R Filipczak, TDT Le, M Zdravkovic, J Gumprecht Experimental and clinical endocrinology & diabetes 114 (08), 417-423, 2006 | 211 | 2006 |
| Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles AJ Krentz, K Fujioka, M Hompesch Diabetes, Obesity and Metabolism 18 (6), 558-570, 2016 | 165 | 2016 |
| Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects A de la Peña, M Riddle, LA Morrow, HH Jiang, H Linnebjerg, A Scott, ... Diabetes care 34 (12), 2496-2501, 2011 | 152 | 2011 |
| Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes A Digenio, RL Dunbar, VJ Alexander, M Hompesch, L Morrow, RG Lee, ... Diabetes care 39 (8), 1408-1415, 2016 | 151 | 2016 |
| Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial GR Fulcher, JS Christiansen, G Bantwal, M Polaszewska-Muszynska, ... Diabetes Care 37 (8), 2084-2090, 2014 | 145 | 2014 |
| Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes N Freemantle, L Blonde, D Duhot, M Hompesch, R Eggertsen, ... Diabetes care 28 (2), 427-428, 2005 | 139 | 2005 |
| Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes S Sha, D Devineni, A Ghosh, D Polidori, M Hompesch, S Arnolds, ... PLoS One 9 (8), e105638, 2014 | 90 | 2014 |
| Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection RJ Pettis, B Ginsberg, L Hirsch, D Sutter, S Keith, E McVey, NG Harvey, ... Diabetes technology & therapeutics 13 (4), 435-442, 2011 | 88 | 2011 |
| A novel insulin formulation with a more rapid onset of action S Steiner, M Hompesch, R Pohl, P Simms, F Flacke, T Mohr, A Pfützner, ... Diabetologia 51, 1602-1606, 2008 | 88 | 2008 |
| Biosimilar insulins: how similar is similar? L Heinemann, M Hompesch Journal of diabetes science and technology 5 (3), 741-754, 2011 | 74* | 2011 |
| Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase L Morrow, DB Muchmore, M Hompesch, EA Ludington, DE Vaughn Diabetes care 36 (2), 273-275, 2013 | 72 | 2013 |
| Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase M Hompesch, DB Muchmore, L Morrow, DE Vaughn Diabetes care 34 (3), 666-668, 2011 | 69 | 2011 |
| Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals T Garito, R Roubenoff, M Hompesch, L Morrow, K Gomez, D Rooks, ... Diabetes, obesity and metabolism 20 (1), 94-102, 2018 | 67 | 2018 |
| Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin L Heinemann, R Baughman, A Boss, M Hompesch Journal of diabetes science and technology 11 (1), 148-156, 2017 | 58 | 2017 |
| First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type … A Kapur, R O’Connor-Semmes, EK Hussey, RL Dobbins, W Tao, ... BMC Pharmacology and Toxicology 14, 1-11, 2013 | 54 | 2013 |
| Biosimilar insulins: basic considerations L Heinemann, M Hompesch Journal of diabetes science and technology 8 (1), 6-13, 2014 | 52 | 2014 |
| Steady state is reached within 2–3 days of once‐daily administration of degludec, a basal insulin with an ultralong duration of action: 每日 1 次给予德谷胰岛素 (一种持续作用时 … T Heise, S Korsatko, L Nosek, HV Coester, S Deller, C Roepstorff, S Segel, ... Journal of diabetes 8 (1), 132-138, 2016 | 51 | 2016 |
| Co‐administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction L Morrow, M Hompesch, H Guthrie, D Chang, DJ Chatterjee Diabetes, Obesity and Metabolism 13 (1), 75-80, 2011 | 51 | 2011 |
Linda MorrowProScientoVerified email at prosciento.com
